undamentalytics Newsletter
Sign in

CG Oncology, Inc. (CGON) stock

Add to watchlist

Add holding +

NASDAQ: CGON Nasdaq Biotechnology Next results ~November 9, 2026

C Fundamentals grade

CG Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$16

Growth cash-flow model

Base case. Range ~$13–$19. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

CG Oncology, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 2 selling1 purchase and 17 sales by directors and officers, last 12 monthsInsider trades
  • Funds123 adding, 109 cuttingOf 47 active managers that changed their stake, 22 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter CG Oncology files

Where CG Oncology stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $6m, up 1030.3% on a year earlier, faster than the 666.0% growth a quarter earlier. That growth ranks 9 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -2879.6% from -17069.9% a year earlier. Operating margin widened to -4056.2% from -28546.1%. The diluted share count is up 14.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 5 of our 6 financial-health checks.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

CG Oncology, Inc.'s trailing-twelve-month revenue grew 1030.3% year on year, with a free-cash-flow margin of -2879.6%. Where it stands out: change in growth rate of +364.3pp ranks 10 of 172 biotechnology companies we cover. Where it lags: stock pay as % of revenue of 567.2% ranks 166 of 179 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 1030.3% (+364.3pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 1030.3% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 364.3 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 24489.9 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -4056.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -2879.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 567.2% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 14.1% in a year.
  • High sales multiple. The shares trade at 820 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.90 against an average estimate of -$0.64: missed by 40.1%
Revenue
$1m
Share reaction
+3.7% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$0.81

CG Oncology's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.2%
  • 1 week+0.6%
  • 1 month-8.0%
  • This year+49.2%
  • 1 year+43.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$6.2M
Operating margin
-4056.2%
Net margin
-3602.7%
EPS (TTM, diluted)
$-2.72

Growth

Revenue growth
+1030.3%
Change in growth rate
+364.3 pts
Share count change
+14.1%

Cash

Free cash flow (TTM)
-$179M
FCF margin
-2879.6%
Stock pay % of revenue
567.2%

Earnings

Last results
August 6, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

CG Oncology, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value CG Oncology, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.29 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$16 ~$13–$19 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.9 ~$3.0–$11 Left out: out of range vs price (0.05x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$16 ~$13–$19 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare CG Oncology, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025Now
Share price$28.68$41.52$61.96
Market value$1.8bn$3.2bn$5.1bn
+ Net debt (− = net cash)−$257m−$29m−$17m
Enterprise value$1.5bn$3.2bn$5.1bn
Multiples
Price / sales n/mn/mn/m
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $534480 and EPS of −$0.81 (range −$0.96 to −$0.66) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.23 −55% $4m +10%
Next −$3.02 +7% $84m +1775%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +20.9% on 90 days ago. In the last 30 days, 0 analysts raised CG Oncology, Inc.'s forecast and 10 cut it.

Consensus EPS forecast CG Oncology, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.67 Current fiscal year, 60 days ago: −$3.20 Current fiscal year, 30 days ago: −$3.23 Current fiscal year, 7 days ago: −$3.23 Current fiscal year, Now: −$3.23 −$3.23 Next fiscal year, 90 days ago: −$2.75 Next fiscal year, 60 days ago: −$3.02 Next fiscal year, 30 days ago: −$3.02 Next fiscal year, 7 days ago: −$3.02 Next fiscal year, Now: −$3.02 −$3.02

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.67−$2.75
60 days ago −$3.20−$3.02
30 days ago −$3.23−$3.02
7 days ago −$3.23−$3.02
Now −$3.23−$3.02

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.64 −$0.90 −40.1%
Mar 2026 −$0.54 −$0.71 −31.5%
Dec 2025 −$0.58 −$0.51 +12.6%
Sept 2025 −$0.55 −$0.57 −4.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026

No numeric guidance in CG Oncology, Inc.'s latest earnings release (filed August 6, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

15 analysts, Oct 2026
Buy1493%
Hold17%
Sell00%

Monthly trend

  1. Oct 202641015
  2. Sep 202641015
  3. Aug 202641015
  4. Jul 202641015

Counts of recommendations published by analysts covering CG Oncology, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.2%
of tradable shares
Days to cover
8.13
at average volume
Short interest, 1 month
−21%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.2%
of shares
Employees
142
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +43.2%

$43.27 on October 31, 2025 to $61.96

ThenNowEffect
Revenue (last 12 months) $551000 $6m +1030.3%
P/S multiple n/m n/m −85.5%
Share count 72m 82m −12.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20252026 to date
Return
CGON+45%+49%
Industry peers (median)−5%−27%
S&P 500+18%+11%
Months that ended higher
CGON67%55%
S&P 50075%46%
Largest fall from a high during the year
CGON−50%−27%
S&P 500−19%−9%

Worst fall since January 25, 2024: 68% from February 16, 2024 to April 8, 2025. Getting back needed a 207% gain, reached on January 9, 2026, 276 days after the low.

Price behaviour

52-week range
$37.37 – $80.68
From 52-week high
−23.2%
vs 50-day average
−10.3%
vs 200-day average
−6.0%
Volatility (1 year)
56%
Beta vs S&P 500
1.07

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 5 down
typical move ±6.2%
After a week
6 up, 4 down
typical move ±10.9%
After a month
7 up, 3 down
typical move ±13.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +3.7% +0.5% +3.2% +3.1%
May 8, 2026 +0.2% +1.1% −3.3% −18.1%
February 27, 2026 +2.9% −0.4% +10.3% +14.0%
November 14, 2025 +9.2% −0.9% +12.4% +0.2%
August 8, 2025 −1.7% +0.6% +5.5% +37.5%
May 13, 2025 −3.9% +0.8% +5.6% +5.3%
March 28, 2025 −9.1% −1.4% −36.2% 0.0%
November 12, 2024 −11.4% −0.3% −17.4% −27.3%
August 8, 2024 +8.3% +2.8% +10.8% +22.1%
May 9, 2024 −12.1% +0.7% −4.5% +8.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

CG Oncology, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) CG Oncology, Inc.
$0 $2M $4M $6M $8M FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY23 Q4: $204K Revenue (TTM), FY24 Q1: $539K Revenue (TTM), FY24 Q2: $650K Revenue (TTM), FY24 Q3: $684K Revenue (TTM), FY24 Q4: $1.1M Revenue (TTM), FY25 Q1: $662K Revenue (TTM), FY25 Q2: $551K Revenue (TTM), FY25 Q3: $2.2M Revenue (TTM), FY25 Q4: $4M Revenue (TTM), FY26 Q1: $5.1M Revenue (TTM), FY26 Q2: $6.2M $6.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $204K
FY24 Q1 $539K
FY24 Q2 $650K
FY24 Q3 $684K
FY24 Q4 $1.1M
FY25 Q1 $662K
FY25 Q2 $551K
FY25 Q3 $2.2M
FY25 Q4 $4M
FY26 Q1 $5.1M
FY26 Q2 $6.2M
Revenue growth, TTM YoY CG Oncology, Inc.
-500% 0% 500% 1000% 1500% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY24 Q4: 458.3% Revenue growth, TTM YoY, FY25 Q1: 22.8% Revenue growth, TTM YoY, FY25 Q2: -15.2% Revenue growth, TTM YoY, FY25 Q3: 217.8% Revenue growth, TTM YoY, FY25 Q4: 254.7% Revenue growth, TTM YoY, FY26 Q1: 666.0% Revenue growth, TTM YoY, FY26 Q2: 1030.3% 1030.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q4 458.3%
FY25 Q1 22.8%
FY25 Q2 -15.2%
FY25 Q3 217.8%
FY25 Q4 254.7%
FY26 Q1 666.0%
FY26 Q2 1030.3%
Operating margin (TTM) CG Oncology, Inc.
-30000% -20000% -10000% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY23 Q4: -27178.9% Operating margin (TTM), FY24 Q1: -12651.8% Operating margin (TTM), FY24 Q2: -12572.3% Operating margin (TTM), FY24 Q3: -14031.0% Operating margin (TTM), FY24 Q4: -10067.3% Operating margin (TTM), FY25 Q1: -20302.3% Operating margin (TTM), FY25 Q2: -28546.1% Operating margin (TTM), FY25 Q3: -8285.3% Operating margin (TTM), FY25 Q4: -4722.1% Operating margin (TTM), FY26 Q1: -4239.0% Operating margin (TTM), FY26 Q2: -4056.2% -4056.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -27178.9%
FY24 Q1 -12651.8%
FY24 Q2 -12572.3%
FY24 Q3 -14031.0%
FY24 Q4 -10067.3%
FY25 Q1 -20302.3%
FY25 Q2 -28546.1%
FY25 Q3 -8285.3%
FY25 Q4 -4722.1%
FY26 Q1 -4239.0%
FY26 Q2 -4056.2%
FCF margin (TTM) CG Oncology, Inc.
-20000% -15000% -10000% -5000% 0% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY24 Q4: -6931.3% FCF margin (TTM), FY25 Q1: -12419.3% FCF margin (TTM), FY25 Q2: -17069.9% FCF margin (TTM), FY25 Q3: -5387.7% FCF margin (TTM), FY25 Q4: -3279.2% FCF margin (TTM), FY26 Q1: -3163.8% FCF margin (TTM), FY26 Q2: -2879.6% -2879.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q4 -6931.3%
FY25 Q1 -12419.3%
FY25 Q2 -17069.9%
FY25 Q3 -5387.7%
FY25 Q4 -3279.2%
FY26 Q1 -3163.8%
FY26 Q2 -2879.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 1 4 6
EBITDA −55 −115 −189 −250
Operating income −55 −115 −191 −253
Net income −49 −88 −161 −224
Diluted EPS −$1.04 −$1.41 −$2.08 −$2.72
Growth (year on year)
Revenue — +458.3% +254.7% +>999%
Margins
EBITDA margin <−999% <−999% <−999% <−999%
Operating margin <−999% <−999% <−999% <−999%
Net margin <−999% <−999% <−999% <−999%
Free-cash-flow margin — <−999% <−999% <−999%
Cash flow
Cash from operations −46 −79 −132 −178
Capital spending — 0 0 1
Free cash flow — −79 −132 −179
Stock-based pay 2 11 27 35
Free cash flow after stock pay — −90 −159 −215
Balance sheet
Cash 8 257 32 20
Total debt 0 0 3 3
Net debt (negative = net cash) −8 −257 −29 −17
Diluted shares 65m 62m 77m 82m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 6 checks passed · June 30, 2026
What it owns · $1.1bn
Short-term assets $1.0bnLonger-term assets $36m
What it owes, and who funded it · $1.1bn
Short-term liabilities $47mLonger-term liabilities $9mShareholders' equity $1.0bn
  • Short-term assets cover short-term liabilities $1.0bn of assets due within a year against $47m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.0bn short-term assets against $9m of longer-dated liabilities.
  • More cash than debt $20m of cash against $3m of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$178m of operating cash flow against $3m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From CG Oncology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+14.1%
year over year
R&D spending
2508.5%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CGON FATE HCWB TSHA TCRX IMRN Median
Revenue, last 12 months $6m $6m $7m $5m $7m $5m $56m
Revenue growth, last 12 months >999% −23.4% 700.2% −32.3% 2.2% 10.9% 12.6%
Revenue growth, 3-year average — −62.1% 20.4% — −24.3% — 13.7%
Revenue growth, latest quarter >999% 9.2% >999% −100.0% −65.8% — 10.2%
Gross margin — — 96.7% — — 64.5% 82.9%
Operating margin <−999% <−999% −115.3% <−999% <−999% −49.9% −189.4%
Operating margin, 3-year average <−999% <−999% −856.2% <−999% <−999% −211.3% −363.5%
Net margin <−999% <−999% −83.8% <−999% <−999% −47.7% −169.8%
Cash from operations / revenue <−999% <−999% −182.1% <−999% <−999% −42.3% −168.0%
Free-cash-flow margin <−999% <−999% −182.1% <−999% <−999% −42.3% −162.4%
Free-cash-flow margin, 3-year average — <−999% −759.7% <−999% <−999% <−999% −310.0%
Stock pay / revenue 567.2% 274.8% 3.4% 331.3% 138.4% 1.1% 20.0%
Change in share count 14.1% 1.2% −47.7% 31.1% 4.1% 28.6% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 1030.3% 12.6% 11 of 172
Change in growth rate Growth +364.3pp -0.1pp 10 of 172
Operating margin Profitability -4056.2% -189.4% 156 of 175
Net margin Profitability -3602.7% -157.3% 162 of 180
Free-cash-flow margin Cash generation -2879.6% -145.4% 159 of 176
Stock pay as % of revenue Cash generation 567.2% 19.2% 166 of 179
Long-term debt as % of assets Balance sheet 0.3% 20.6% 13 of 78
Change in share count Balance sheet 14.1% 7.9% 102 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Commercial and Development Revenue $3.2M 80.0% —
License and Collaboration Revenue $806,000 20.0% ▼ 29.2%

From CG Oncology, Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$6.7B
Institutions reporting
227
Shares held vs prior quarter
▲ 6.2%
Positions opened / closed
31 / 37

Top buyers and sellers, Q2 2026: 123 institutions bought and 109 sold ; the biggest buyer was Seven Fleet Capital Management LP (+1.8M shares) and the biggest seller Driehaus Capital Management LLC (−1000K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RTW Investments, LP $605M 8.5M 9.1% ▲ 21.9%
T. Rowe Price Investment Management, Inc. $470M 6.6M 7.1% ▼ 1.5%
Decheng Capital LLC $453M 6.4M 6.8% 0.0%
Blackrock, Inc. $445M 6.3M 6.7% ▲ 23.5%
Wellington Management Group LLP $378M 5.3M 5.7% ▼ 0.9%
FMR LLC $296M 4.2M 4.4% ▲ 10.5%
Price T Rowe Associates Inc $270M 3.8M 4.1% ▲ 4.2%
Tcg Crossover Management, LLC $261M 3.7M 3.9% 0.0%
Vanguard Portfolio Management LLC $246M 3.5M 3.7% ▲ 12.0%
State Street Corp $244M 3.4M 3.7% ▲ 29.9%
Vanguard Capital Management LLC $236M 3.3M 3.5% ▲ 9.3%
Foresite Capital Management Vi LLC $168M 2.4M 2.5% ▲ 6.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not CG Oncology, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $24.8M 1 trade by 1 insider, last 12 months Insider sales History → $4.8M 17 trades by 2 insiders · 100% under pre-set plans
Net ▲ $20M net buying
Insider Date Trade Shares Price Value
Post Leonard E Director October 15, 2026 Sell pre-set plan 500 $62.48 $31,240
Post Leonard E Director October 15, 2026 Sell pre-set plan 500 $61.65 $30,825
Post Leonard E Director September 15, 2026 Sell pre-set plan 1,000 $72.98 $72,980
Post Leonard E Director August 14, 2026 Sell pre-set plan 1,000 $74.54 $74,540
Post Leonard E Director July 15, 2026 Sell pre-set plan 1,000 $71.17 $71,170
Mulay James Director July 10, 2026 Sell pre-set plan 24,165 $75.16 $1.8M
Liu Brian Guan-Chyun Director June 25, 2026 Buy pre-set plan 371,085 $66.87 $24.8M
Post Leonard E Director June 24, 2026 Sell pre-set plan 5,000 $70.00 $350,000
Post Leonard E Director June 22, 2026 Sell pre-set plan 5,000 $65.00 $325,000
Mulay James Director June 15, 2026 Sell pre-set plan 654 $60.12 $39,318
Mulay James Director June 15, 2026 Sell pre-set plan 1,310 $60.12 $78,757
Post Leonard E Director June 4, 2026 Sell pre-set plan 1,000 $54.50 $54,500

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 8, 2026
  • February 27, 2026
  • November 14, 2025
  • August 8, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on CG Oncology, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

CG Oncology, Inc. in brief

What does CG Oncology, Inc. do?
CG Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is CG Oncology, Inc.'s stock ticker?
CG Oncology, Inc. trades under the ticker CGON on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is CG Oncology, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, CG Oncology, Inc. reported revenue of $6.2M, 1030.3% higher than a year earlier, according to its SEC filings.
What is CG Oncology, Inc.'s free cash flow?
CG Oncology, Inc.'s free-cash-flow margin is -2879.6% of revenue over the trailing twelve months, ranking 159 of the 176 biotechnology companies we cover.
Who are CG Oncology, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RTW Investments, LP, T. Rowe Price Investment Management, Inc. and Decheng Capital LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is CG Oncology, Inc.'s market cap?
On November 2, 2026, CG Oncology, Inc.'s market capitalisation was about $5.1B and net debt of -$16.6M. Market figures come from third-party market data and may be delayed.
How much debt does CG Oncology, Inc. have?
CG Oncology, Inc.'s debt-to-equity ratio is 0.3%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are CG Oncology, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to CG Oncology, Inc. are Fate Therapeutics Inc, HCW Biologics Inc., Taysha Gene Therapies, Inc., Tscan Therapeutics, Inc. and Immuron Ltd. The side-by-side comparison below sets their revenue, margins and growth against CG Oncology, Inc.'s.
Are insiders buying or selling CG Oncology, Inc. stock?
Over the last 12 months, CG Oncology, Inc.'s directors and officers reported 1 open-market purchases and 17 sales on Form 4. The insider trading page charts every trade.
When is CG Oncology, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — CG Oncology, Inc. announces its own schedule.